VRT106 with chemotherapy for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new treatment called VRT106 combined with chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with advanced pancreatic cancer that cannot be removed by surgery.
- You have not had prior chemotherapy or other systemic treatment for your advanced pancreatic cancer.
- You have at least one tumor that can be measured on a scan.
- You are generally able to take care of yourself (ECOG score 0 or 1).
- You are not pregnant or breastfeeding, and you do not have a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called VRT106 combined with chemotherapy for people with pancreatic cancer that can be surgically removed. The goal is to see if the combination works better than standard treatment alone.
This trial tests giving a combination of an oncolytic virus, immunotherapy (PD-1 inhibitor), and chemotherapy before surgery to shrink pancreatic tumors and make them easier to remove. The goal is to improve outcomes for people with borderline resectable or locally advanced pancreatic cancer.
This trial tests a new treatment that combines a cancer-killing virus with an immunotherapy drug (a PD-1 inhibitor) for advanced pancreatic cancer. It aims to see if this combination can help shrink tumors and improve outcomes for patients who have already tried chemotherapy.
This trial tests a new immunotherapy drug (ivonescimab) combined with targeted radiation and chemotherapy for people with pancreatic cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a new drug combination for pancreatic cancer that has not been treated before. It may help shrink tumors or make surgery possible for people with advanced or borderline resectable disease.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.